Form 4: REGENXBIO CFO Mitchell Chan Reports Stock and Option Awards

REGENXBIO's Chief Financial Officer, Mitchell Chan, reports the acquisition of restricted stock units and stock options.

Summary

• Mitchell Chan, the Chief Financial Officer of REGENXBIO Inc., reported the acquisition of 58,869 shares of common stock and 289,362 stock options on September 16, 2024.
• The common stock was acquired through a restricted stock unit (RSU) award.
• The RSUs vest in equal installments over four years, starting on the first day of the month in which the RSU was granted, contingent upon continuous service.
• The stock options have a term of 10 years and vest over four years, with 1/4 vesting after 12 months of continuous service and the remaining 1/48 vesting monthly thereafter, also contingent upon continuous service.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options and RSUs, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance.

Industry Context

Stock and option awards are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also utilize similar equity-based compensation plans for their executives.
• The vesting schedules (4 years) are also typical within the industry.

Stakeholder Impact

• The stock and option awards incentivize the CFO to drive long-term value for shareholders.
• Employees may be indirectly impacted by the CFO's performance and strategic decisions.

Key Dates